OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects G...
December 01 2020 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its group
company and wholly owned subsidiary Ares Genetics GmbH (Vienna,
Austria; “Ares Genetics”) has extended its collaboration with
Sandoz within its pharma partnering program. Also, Ares Genetics
expects to present advances of its research use only (RUO) based
ares-genetics.cloud platform for predictive antibiotic
susceptibility testing (AST) at various scientific conferences and
expects granting of key patent on genetic resistance prediction.
Ares Genetics and Sandoz, the #1 supplier of
generic antibiotics globally, have extended their collaboration
under a strategic collaboration agreement with the overall goal to
develop a digital anti-infectives platform combining established
microbiology laboratory methods with advanced bioinformatics and
artificial intelligence methods to support drug development and
life cycle management. The next phase of the collaboration aims at
further leveraging molecular predictive AST and follows the
presentation of final results from the initial collaboration phase
on optimal positioning of fosfomycin and fosfomycin combination
therapies by molecular antibiotic susceptibility testing and in
silico modeling at the Antimicrobial Resistance – Genomes, Big Data
and Emerging Technologies virtual conference in early November of
this year.
Recent advances of Ares Genetics’
ares-genetics.cloud platform enabling accurate and rapid
next-generation sequencing (NGS)-based AST using Oxford Nanopore
Technology long-read sequencing are scheduled to be presented at
the virtual Sequencing, Finishing and Analysis in the Future
Meeting, from December 1 to 3, by Ares Genetics’ Head of
Bioinformatics & Analytics Dr. Stephan Beisken, who leads the
development. In addition, data is scheduled to be presented at the
ASM Conference on Rapid Applied Microbial Next-Generation
Sequencing and Bioinformatics Pipelines, from December 7 to 11 by,
Dr. Patricia Simner from Johns Hopkins Medicine, who collaborates
with the Ares Genetics team on developing next-generation
sequencing based antibiotic susceptibility testing solutions.
Alongside these latest technology development
achievements, Ares Genetics has further expanded its intellectual
property (IP) portfolio and technology position in data-driven
infectious disease diagnostics and recently received communication
that the examining division of the European Patent Office intends
to grant a European patent for European Patent Application No. 16
751 551.9 “Genetic resistance prediction against antimicrobial
drugs in microorganism using structural changes in the genome.”
“We’re thrilled about our continued progress in
developing and commercializing much needed solutions for rapid
predictive antibiotic susceptibility testing using next-generation
sequencing as well as the growing demand for our
testing-as-a-service and interpretation-as-a-service offerings
enabled by patent-pending AI-powered technology,” commented Dr.
Andreas Posch, CEO Ares Genetics. He added, “I am particularly
excited about our collaboration with Sandoz on optimal antibiotic
drug positioning based on molecular testing as well as our joint
work with Johns Hopkins demonstrating feasibility of accurate AST
prediction using long-read sequencing technology as this technology
could potentially allow for rapid predictive AST directly from
native patient samples.”
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we
are developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements by
OpGen
This press release includes statements regarding
OpGen’s collaboration with Sandoz and the expected grant of a key
patent on genetic resistance prediction. These statements and other
statements regarding OpGen’s future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, the rate of adoption of our
products and services by hospitals and other healthcare providers,
the fact that we may not effectively use proceeds from recent
financings, including our November 2020 private placement, the
realization of expected benefits of our business combination
transaction with Curetis GmbH, the success of our commercialization
efforts, the impact of COVID-19 on the Company’s operations,
financial results, and commercialization efforts as well as on
capital markets and general economic conditions, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen Contact: Oliver Schacht CEO
InvestorRelations@opgen.com
Press Contact: Matthew Bretzius
FischTank Marketing and PR matt@fischtankpr.com
Investor Contact: Megan Paul
Edison Group mpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024